Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Earmarks 55 Billion Yen for Domestic Antibiotic API Production: Extra Budget
November 10, 2022
- Extra Budget to Cover Enough COVID Vaccine Purchases until Next Winter
November 10, 2022
- METI Looks to Bolster Pharma Startup Ecosystem with 6-Fold Hike in Extra Budget
November 10, 2022
- Skyrizi Auto-Doser Peak Sales Put at 30-Plus Billion Yen, Mounjaro Not on Roster: November Listing
November 10, 2022
- Industry Reiterates Call for Careful Discussions on Off-Year Revision: LDP Confab
November 10, 2022
- 9-Valent HPV Vaccine Program to Start in April, Panel Seeks Early Approval of 2-Dose Regimen
November 9, 2022
- Bill to Amend Infectious Disease Act Clears Lower House
November 9, 2022
- Pharma, Payers Nudge MHLW to Speed Up Data Supply from NDB
November 9, 2022
- MOF Panel Member Calls for Drug Price Cuts to Unleash Innovation, Ease Household Burdens
November 8, 2022
- Japan Panel Recognizes 6 More Deaths Possibly Linked to COVID Vaccines
November 8, 2022
- MOF Proposes Transition to Normal Framework for COVID Vaccines, Therapeutics
November 8, 2022
- MOF Renews Its Push for Full Drug Price Revision in FY2023
November 8, 2022
- Lower House Health Committee OKs Revised Bill to Amend Infectious Disease Act
November 7, 2022
- CEFP Will Thoroughly Discuss Drug Pricing and Discovery: Minister
November 4, 2022
- Moderna’s BA.4/5 COVID Booster Nabs Special Approval in Japan
November 1, 2022
- Label Expansion for TS-1, Enhertu and More in Line for November Approval
November 1, 2022
- MHLW Panel Puts Pfizer’s Precedex on Hold for Pediatric Indication
October 31, 2022
- Deloitte Proposes Pricing Schemes to Encourage Consolidation of Generic Makers
October 31, 2022
- Aricept’s Lewy Body Dementia Indication to Be Modified after Post-Launch Trial Miss
October 31, 2022
- MHLW Panel OKs 100 More Health Damage Claims for COVID-19 Vaccines
October 31, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…